Fairvalue-Calculator Fairvalue-Calculator
EN DE

Curis, Inc (CRIS) Fair Value & Analysis

Healthcare · US · Market cap $16.4M

Price$0.3617
Fair Value$0.6300
Upside+74.2%
Quality95/100
Evidence: Low Range $0.4700 – $0.7900

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Curis, Inc (CRIS) currently trades at $0.3617, while our model-based Fair Value estimate is $0.6300 — implying the stock looks roughly 74.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pat…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Curis, Inc (CRIS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.6300 versus a price of $0.3617 — about +74% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CRIS?
Our 21-model fair value for Curis, Inc is $0.6300 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.3617.
What is the quality score of CRIS?
Curis, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.